Aspen to pay $9.7M to settle U.K. competition concerns
By 
Neil Hodge2019-08-15T18:08:00
Aspen Pharmacare has offered to pay the U.K.’s National Health Service £8 million (U.S. $9.7 million) following suspicions that the company paid rival firms to delay marketing a vital medicine to retain market dominance.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleQ&A with Isabella Agius, client compliance head at Apex Group: AML keeps EU fund managers awake
Anti-money-laundering rules are the chief compliance concern for fund managers – and other sectors should take note – according to Isabella Agius, product head, corporate solutions, in the client compliance and regulatory services at Apex Group.
-
ArticleSanctions enforcement set to increase, but gaps and inconsistency create compliance risks
Geopolitical volatility is causing rapidly changing sanctions regimes, but diverging rules in different jurisdictions create enforcement gaps that are exploited by sanctioned individuals and entities – and the routes used to evade sanctions are constantly developing.
-
ArticleFormer telemedicine company owner gets 7 years for role in $136M kickback scheme
A former co-owner of two telemedicine companies who helped orchestrate $136 million in Medicare fraud was sentenced to seven years in prison for his role in the nationwide bribery and kickback scheme involving orthotic braces, doctors, and false claims.
More from Europe
-
ArticleExperts: P&O Ferries’ exposure of U.K. law weaknesses sets dangerous precedent
P&O Ferries’ dismissal of 800 workers with immediate effect via prerecorded video before consulting unions or employees has united U.K. politicians of all parties to condemn the company. One problem: Its actions appear to be largely legal.
-
ArticleAmazon shuttered in France over COVID-19 emergency costs
E-commerce giant Amazon has shut up shop in France because the cost of compliance with the country’s COVID-19 emergency measures is deemed to be too high.
-
ArticleDon’t count on European regulators to relax rules during coronavirus crisis
European businesses may be putting themselves at risk because they mistakenly believe regulators are prepared to loosen the rules so companies can operate more easily as the coronavirus pandemic lingers on.